Upregulating beta-hexosaminidase activity in rodents prevents alpha-synuclein lipid associations and protects dopaminergic neurons from alpha-synuclein-mediated neurotoxicity by Brekk, Oeystein R. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2020-08-06 
Upregulating beta-hexosaminidase activity in rodents prevents 
alpha-synuclein lipid associations and protects dopaminergic 
neurons from alpha-synuclein-mediated neurotoxicity 
Oeystein R. Brekk 
Harvard Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Lipids 
Commons, Nervous System Commons, Nervous System Diseases Commons, Neurology Commons, 
Neuroscience and Neurobiology Commons, and the Nutritional and Metabolic Diseases Commons 
Repository Citation 
Brekk OR, Korecka JA, Crapart CC, Huebecker M, MacBain ZK, Rosenthal SA, Sena-Esteves M, Priestman 
DA, Platt FM, Isacson O, Hallett PJ. (2020). Upregulating beta-hexosaminidase activity in rodents prevents 
alpha-synuclein lipid associations and protects dopaminergic neurons from alpha-synuclein-mediated 
neurotoxicity. Open Access Articles. https://doi.org/10.1186/s40478-020-01004-6. Retrieved from 
https://escholarship.umassmed.edu/oapubs/4303 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
RESEARCH Open Access
Upregulating β-hexosaminidase activity in
rodents prevents α-synuclein lipid
associations and protects dopaminergic
neurons from α-synuclein-mediated
neurotoxicity
Oeystein R. Brekk1, Joanna A. Korecka1,2, Cecile C. Crapart1, Mylene Huebecker3,4, Zachary K. MacBain1,
Sara Ann Rosenthal1, Miguel Sena-Esteves5, David A. Priestman3, Frances M. Platt3, Ole Isacson1* and
Penelope J. Hallett1*
Abstract
Sandhoff disease (SD) is a lysosomal storage disease, caused by loss of β-hexosaminidase (HEX) activity resulting in
the accumulation of ganglioside GM2. There are shared features between SD and Parkinson’s disease (PD). α-synuclein
(aSYN) inclusions, the diagnostic hallmark sign of PD, are frequently found in the brain in SD patients and HEX knockout
mice, and HEX activity is reduced in the substantia nigra in PD. In this study, we biochemically demonstrate that HEX
deficiency in mice causes formation of high-molecular weight (HMW) aSYN and ubiquitin in the brain. As expected from
HEX enzymatic function requirements, overexpression in vivo of HEXA and B combined, but not either of the subunits
expressed alone, increased HEX activity as evidenced by histochemical assays. Biochemically, such HEX gene expression
resulted in increased conversion of GM2 to its breakdown product GM3. In a neurodegenerative model of overexpression
of aSYN in rats, increasing HEX activity by AAV6 gene transfer in the substantia nigra reduced aSYN embedding in lipid
compartments and rescued dopaminergic neurons from degeneration. Overall, these data are consistent with a paradigm
shift where lipid abnormalities are central to or preceding protein changes typically associated with PD.
Keywords: α-Synuclein, β-Hexosaminidase, Sandhoff disease, Parkinson’s disease, Neuroprotection, Lipid binding
Introduction
Age-related neurodegenerative diseases, such as Parkinson’s
disease (PD), have many etiological roots that converge on
mitochondrial, lipid, protein and inflammatory pathological
mechanisms [16, 19]. Lysosomal storage diseases (LSDs)
are a class of more than 70 metabolic disorders typically
characterized by autosomal recessive loss-of-function
mutations in lipolytic hydrolases and the concurrent accu-
mulation of the associated lipid substrate [32, 34]. Among
these enzymes is β-hexosaminidase (HEX), which is re-
sponsible for turnover of the glycosphingolipid ganglioside
GM2 [51]. There are three separate isoforms of HEX,
generated by combined expression from the two gene loci
HEXA and HEXB: the HEX A isoform, consisting of a
HEXα +HEXβ heterodimer, and two homodimers consist-
ing of subunits HEXβ+HEXβ (HEX B) and HEXα+HEXα
(HEX S) [2]. Impaired GM2 catabolism causes two clinic-
ally similar diseases, which are classified depending on
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which locus is mutated: Tay-Sachs disease (HEXA) and
Sandhoff disease (SD) (HEXB) [6]. In both cases, the net ef-
fect is loss of the HEX A+B heterodimer, and both dis-
eases are characterized by neuronal swelling and
degeneration caused by elevated ganglioside storage [41].
PD, which affects nearly 4 in 100 people over the
course of a lifetime [26], characterized by progressive
loss of dopaminergic neurons of the substantia nigra
pars compacta (SNpc) and concurrent aggregation
of the synapse-associated protein α-synuclein (aSYN)
[35], shares many pathophysiological features associated
with LSDs. GBA1 encodes the lysosomal hydrolase glu-
cocerebrosidase (GCase), responsible for catabolizing the
glycosphingolipids glucosylceramide and glucosylsphin-
gosine, and it is the causative gene in the LSD Gaucher
disease (GD) [14]. Haploinsufficiency caused by carrier
mutations in GBA1 constitute the strongest genetic risk
factor for PD, accounting for 7–10% of cases [46], and
exome-wide analysis of 53 LSD-related genes, including
HEXB, showed an overall association of rare variants
with PD - although the variation was also high in the
healthy subject population [37]. Genome-wide associ-
ation studies have also identified PD risk variants in
three additional lysosomal genes (GUSB, GRN, and
NEU1) [56], and cell-type specific enrichment of lyso-
somal genes have demonstrated associations to PD herit-
ability when selecting for astrocytic, microglial and
oligodendroglial subtypes [36]. Enzymatic activity of
both GCase and HEX are progressively lost with age in
PD [17, 38], with HEX-activity only showing significant
downregulation compared to healthy subject controls
in patients aged 80 years or older [17, 28]. GD- [52]
and SD [48] patient brains show evidence of aSYN ag-
gregation. Experimentally, both pharmacological inhib-
ition of GCase and targeted deletion of the HEXB locus
produce aSYN aggregation in mice [9, 39, 49]. In human
PD brains and mouse models characterized by impaired
glycolipid metabolism, aSYN exists within lipid compart-
ments and forms high molecular weight (HMW) species
undetectable to conventional biochemical assays [7, 20,
45]. Furthermore, the presence of aSYN pathology in GD-
and SD- patient samples and experimental models redu-
cing either GCase or HEX activity is interesting because it
highlights the role of lysosomal enzymes in this classic
pathology. The overall importance of lipid catabolism and
turnover is highlighted by the recent findings that the
major components of the pathology for PD, Lewy bodies,
are lipids. Such Lewy bodies, coated by aSYN, were shown
to be predominantly composed of a wide variety of lipid-
containing subcellular components, including vesicles, or-
ganelles, and disordered membranes [44].
Gangliosides are enriched in neurons, where they pre-
dominantly localize to the outer leaflet of the plasma
membrane in specialized lipid microdomains termed
‘lipid rafts’ [47], and the primary proposed physiological
interaction of aSYN with gangliosides is localization to
synaptic terminals through binding of lipid raft domains
[12]. Though originally believed to be exclusively neur-
onal constituents, relative abundances of certain species
of gangliosides (e.g. GM3) are higher in astrocytic lipid
rafts than in neurons [1], and it is possible GM2/GM3
localization plays an additional role in neuron-glia
interactions.
In this study, we first aimed to biochemically
characterize aSYN changes in the transgenic HEXB−/−
SD mouse model with GM2 gangliosidoses. Given that
complete loss of ability to hydrolyse GM2 in the lyso-
some because of HEXB loss causes PD-like accumulation
of aSYN [9, 49], we hypothesized that increased HEX ac-
tivity could protect neurons from neurotoxicity associ-
ated with experimentally induced aSYN accumulation.
To this end, we utilized a recombinant adeno-associated
viral (AAV6) vector strategy to specifically overexpress
aSYN ~ 3-fold in the vulnerable dopaminergic neurons
of the rat SNpc, which causes progressive degeneration
of the nigrostriatal circuit with concurrent aSYN accu-
mulation [21, 50, 54], combined with AAV6-mediated
expression of HEXA and HEXB. We found that upregu-
lated HEX activity rescued degeneration of rat dopamin-
ergic neurons and limited interactions between lipid
compartments and overexpressed aSYN.
Methods
Recombinant adeno-associated viral vector preparation
The AAV6-aSYN vector contains a coding sequence for
human WT-aSYN under the control of a synapsin-1
promoter. The titer of AAV6-aSYN stock was 2.42 ×
1012 viral genome copies (vgcs) / mL. AAV6 promoter-
free empty vector (EV) control virions were acquired
from Virovek (Hayward CA, USA), and the final titer
was estimated to be 2 × 1012 by qPCR, followed by SDS-
PAGE electrophoresis. AAV6-HEXA and AAV6-HEXB
vectors contained coding sequences for human HEX A
and HEX B under the control of a CBA promoter re-
gion. The final titer for AAV6-HEXA was 9.32 × 1011
genome copies / mL, and for AAV6-HEXB it was 8.7 ×
1011 genome copies / mL. The AAV6-GFP construct uti-
lized as control in the GM3 HPLC-measurements was
under control of a CBA promoter region, with a final
titer of 1.06 × 1012. The titers were estimated by real-
time quantitive PCR using primers and a Taqman probe
to the bovine growth hormone poly-adenylation site
present in both HEXA and HEXB vectors.
Animals
All animal procedures were performed in accordance
with the guidelines of the National Institute of Health
and were approved by the Institutional Animal Care and
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Use Committee (IACUC) at McLean Hospital, Harvard
Medical School. Animals were housed per standard con-
ditions, in a dark/light cycle of 12 h, with ad libitum ac-
cess to food and water. 12-week-old male (N = 4) and
female (N = 4) WT mice (C57BL/6, Jackson Laborator-
ies, and 11–14-week-old male and female HEXB−/−
Sandhoff mice [42] (N = 8) (obtained from Dr. Miguel
Sena-Esteves) were used in this study. 235-260 g naïve
Sprague-Dawley rats (N = 30) (Charles River Laborator-
ies) were used for all stereotactic surgical experiments.
Stereotactic delivery of AAV6 to the rat substantia nigra
pars compacta
Female Sprague-Dawley rats weighing 235-260 g were
used for all stereotactic surgical experiments. These ex-
periments had previously been approved by the McLean
Hospital Institutional Animal Care and Use Committee
(IACUC). Stereotaxic coordinates for the surgeries were
adapted from prior studies [10]. Animals received a pre-
anesthetic mix of 0.08mg/kg Atropine and 1.7mg/kg
Acepromazine delivered intramuscularly 15 min prior to
anesthesia with xylazine and ketamine (5.4 mg/kg and
72mg/kg, respectively). Prior to fixation in the stereotac-
tic frame, each animal received 1 mg/kg Metacam deliv-
ered subcutaneously. During the surgery, animals
received oxygen at 0.15 mL/min. The animals were
placed in a stereotaxic frame (Kopf), where a 10 μl
Hamilton syringe and 31 gauge needles were used as a
delivery system. All injections were made into the substan-
tia nigra pars compacta using the following anteroposterior
(AP), mediolateral (ML), and dorsoventral (DV) coordinates
as previously verified [23, 54]: AP − 5.2mm, ML − 2.0mm,
DV − 7.2mm. The injection titers of the viruses were 2 ×
1012 vgc/mL for aSYN, and 8.7 × 1011 vgc/mL for HEX A,
B, and EV, and 3 μl were injected per site. For the GM3
measurements, AAV6-GFP was utilized as a control, with
an injection titer of 8.70 × 1011 vgc/mL. The viral deliveries
were done at 0.4 μl/min using a microinfusion pumps
(Stoelting), with a 3min wait, followed by 0.5mm with-
drawal of needle, followed by an additional 1min wait, be-
fore the needle was slowly withdrawn completely.
Anesthesia was reversed post-operatively by Antisedan de-
livered intramuscularly at 1mg/kg.
Immunohistochemistry
Animals were terminally anesthetized with an overdose
of sodium pentobarbital (150 mg/kg, intraperitoneal de-
livery) and perfused intracardially with ice-cold heparin-
ized saline (0.1% heparin in 0.9% saline) followed by
paraformaldehyde (PFA) (4% in PBS). The brains were
removed and postfixed for 24 h in 4% PFA. Following
postfixation, the brains were equilibrated in 20% sucrose
in PBS, sectioned at 40 μm on a freezing microtome, and
serially collected in PBS. Sections were washed three
times in PBS 0.1% Triton-X, blocked in 10% normal goat
serum in PBS 0.3% Triton-X, and primary antibodies
were applied overnight at 4C. Primary antibodies used
were rabbit anti-tyrosine hydroxylase (Pel-Freez Biologi-
cals Cat# P40101, RRID:AB_2313713), mouse anti-aSYN
(human) (Millipore Cat# 36–008, RRID:AB_310817),
mouse anti-aSYN (pan species) (BD Biosciences Cat#
610786, RRID:AB_398107), mouse anti-LAMP-1 (Santa
Cruz Biotechnology Cat# sc-65,236, RRID:AB_831070),
and mouse anti-HEX A (Santa Cruz Biotechnology Cat#
sc-376,777). After primary antibodies, tissues were
washed three times in PBS 0.1% Triton-X, and secondary
antibodies were applied at room temperature in dark for
60 min. Secondary antibodies (goat anti-mouse and anti-
rabbit) were from Thermo-Fisher Scientific (Alexa Fluor
488 (RRID:AB_26633275) & 568 (RRID:AB_141371).
Coverslipping was done utilizing Mowiol (Sigma-Aldrich
Cat# 81381).
Histochemical hexosaminidase activity assay
Animals were decapitated following an overdose of sodium
pentobarbital (150mg/kg, intraperitoneal delivery), and the
brains sectioned at 12 μm thickness through the coronal
plane by cryostat. Following postfixation in 4% PFA for 10
min at room temperature, β-hexosaminidase activity was
detected histologically in fresh-frozen, cryosectioned rat
coronal sections using Naphthol AS-BI-N-acetyl-β-D-glu-
cosaminide (Sigma Aldrich Cat# N4006) as previously de-
scribed [8, 24]. Briefly, sections were incubated in 0.25mM
Naphthol AS-BI-N-acetyl-β-D-glucosaminide in 50mM
Sodium Phosphate Citrate Buffer (pH 5.2) with hexazotized
pararosaniline for 6 h at RT, prior to washing and
coverslipping.
Stereological estimates of tyrosine hydroxylase+
dopaminergic neurons and densitometric analysis of the
dorsolateral striatum
Number of tyrosine hydroxylase (TH)-positive dopamin-
ergic neurons of the substantia nigra pars compacta was es-
timated by an unbiased stereological quantification method
using the optical fractionator principle [5, 18] embedded in
the Stereo Investigator v2019.1.3 software (MBF Bio-
science), a motorized stage (LE2-MB, LUDL electronics)
and a top-mounted camera (ORCA Flash4.0LT, Hamama-
tsu) with the light microscope (Axio Imager M2, Carl Zeiss
Microscopy). Every sixth section throughout the whole
rostro-caudal axis of the substantia nigra was included, re-
gion of interest was outlined with a 2.5x objective and
counting was performed using a 40x objective. Random
start and systematic sampling were applied. Counting pa-
rameters were adjusted to achieve at least 100 counts per
hemisphere. All quantifications and analysis were per-
formed by a single blinded investigator. A coefficient of
error (Gundersen) [15] of 0.1 was accepted. Data are
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expressed as % of the non-injected control hemisphere.
Striatal TH+-density was quantified using 4–6 coronal sec-
tions per brain, covering the whole rostro-caudal axis of the
striatum. Sections were tile-scanned with a 20x objective
using a BZ-X700 fluorescent microscope (Keyence), and
the dorsolateral aspect of the striatum was analyzed in Ima-
geJ (NIH) in the indicated regions (see Fig. 3a), quantifying
average TH+ pixel values. Data were then normalized as %
of the non-injected control hemisphere in each section.
Biochemistry and western blotting
WT- and SD mice were terminally anesthetized with an
overdose of sodium pentobarbital (150 mg/kg, intraperi-
toneal delivery) and perfused intracardially with ice-cold
heparinized saline (0.1% heparin in 0.9% saline). Brains
were extracted and separated by the midline, and half-
brains were spot dissected for substantia nigra and the
dorsolateral aspect of the striatum prior to being frozen
on dry ice for biochemical assays. Lysis of whole-brain
tissues was carried out for 30 min on ice in lysis buffer
(150 mM NaCl, 50 mM Tris pH 7.6, 1% Triton X, 2 mM
EDTA) with protease/phosphatase inhibitors added
(Halt Protease & Phosphatase Inhibitor Cocktail (100X),
Thermo Fisher Scientific Cat# 1861284), and the lysates
sonicated for 30 s (5 s pulses, on ice). Membrane-
enriched fractions were pelleted in 1% Triton-X by ultra-
centrifugation (100,000xG, 1 h, 4C), and reconstituted in
lysis buffer supplemented 2% SDS. The supernatant
from this initial separation constituted the cytosol-
enriched fractions. After 2% SDS-supplemented lysates
were centrifuged again (100,000xG, 1 h, 4C), the super-
natant was collected as the membrane-enriched fraction.
Equal amounts of protein from each fraction was sepa-
rated using polyacrylamide gel electrophoresis (4–20%
Criterion Tris-HCl Protein Gel, Bio-Rad Cat# 3450032).
Primary antibodies included mouse anti-aSYN (pan spe-
cies) (BD Biosciences Cat# 610786, RRID:AB_398107),
rabbit anti-phospho-aSYN (S129) (Cell Signaling Tech-
nology Cat# 23706, RRID:AB_2798868), rabbit anti-
ubiquitin (Agilent Cat# Z0458, RRID:AB_2315524), and
chicken anti-GAPDH (Millipore Cat# AB2302, RRID:
AB_10615768). Protein content of each sample was de-
termined using a bicinchoninic acid (BCA) assay kit
(Thermo Scientific Cat#23225). For delipidation, lysates
were heated on a heating block (65C) for 16 h prior to
addition of Laemmli-buffer, as previously described [45].
Secondary, HRP-conjugated antibodies were anti-mouse
(Trueblot Ultra) (Rockland Cat# 18–8817-33) anti-
chicken (Affinipure) (Jackson Immunoresearch Labora-
tories Cat# 103–035-155), and anti-rabbit (Thermo
Fisher Scientific, A-21206). Chemiluminescent develop-
ment was done using Westernbright Sirius (Advansta
Cat# K-12043-D20), and imaging was done on a Gel
Doc XR+ system (Bio-Rad Cat# 1708195). To ensure
linearity of signal, only images without saturated pixels
were selected for quantifications using the densitometric
western blot plug-in in ImageJ (NIH).
Ganglioside GM3 analysis by NP-HPLC
Ganglioside GM3 content from dissected rat substantia
nigra (SN) injected with AAV6-HEX+aSYN and AAV6-
GFP + aSYN were analyzed as previously described [17,
29]. Briefly, glycosphingolipids (GSLs) were extracted
from rat SN with chloroform/methanol overnight at 4 °C
and further purified using solid-phase C18 columns
(Telos, Kinesis, UK). GSLs were dried down under a
stream of nitrogen at 42 °C and treated with recombin-
ant ceramide glycanase (rEGCase, prepared by Genscript
and provided by Orphazyme, Denmark) to obtain oligo-
saccharides from complex GSLs. Liberated glycans were
then fluorescently labelled with anthranillic acid (2AA).
Excess 2AA label was removed using DPA-6S SPE col-
umns (Supelco, PA, USA). Purified 2AA-labelled glycans
were separated and quantified by normal-phase high-
performance liquid chromatography (NP-HPLC) as pre-
viously described [29]. The NP-HPLC system consisted
of a Waters Alliance 2695 separations module and an
in-line Waters 2475 multi λ-fluorescence detector set at
Ex λ360nm and Em λ425nm. The solid phase used was a
4.6 × 250 mm TSK gel-Amide 80 column (Anachem, Lu-
ton, UK). A 2AA-labelled glucose homopolymer ladder
(Ludger, UK) was used to determine the glucose unit
values (GUs) for the HPLC peaks. GM3 was identified
by its GU value and quantified by comparison of inte-
grated peak areas with a known amount of 2AA-
labelled BioQuant chitotriose standard (Ludger, UK).
Results were normalized to protein content, deter-
mined using bicinchoninic acid (BCA) assay.
Lysosomal β-hexosaminidase activity measurements in
rat substantia nigra
Lysosomal β-hexosaminidase activities were assayed
fluorometrically using an artificial sugar-substrate conju-
gated with the fluorophore 4-methylumbelliferone (4-
MU). The substrate utilized to assess β-hexosaminidase
activity was 3mM 4-MU N-acetyl-β-D-glucosaminide in
200mM sodium citrate buffer, pH 4.5, 0.1% TritonX-100.
The digests (in triplicate) containing tissue homogenate in
PBS with 0.1% TritonX-100 and artificial 4-MU substrate
were incubated at 37 °C for 30min. The reaction was
stopped by adding cold 0.5 M Na2CO3 (pH 10.7). The
released fluorescent 4-MU was measured in a FLUOs-
tar OPTIMA plate reader (BMG Labtech, Ortenberg,
Germany) with an excitation at 360 nm and emission at
460 nm. A standard curve of free 4-MU was used to
calculate the enzyme activity. Results were normalized
to protein content.
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Statistics
Graphpad Prism (v8) was used for all statistics (Graph-
Pad Software, San Diego, California, USA). Two-tailed,
parametric t-tests, or matched sample t-tests, were uti-
lized for single comparisons as indicated in figure leg-
ends. In cases of significantly different variances, the
Welch’s correction was applied. For correlation analysis,
Pearson’s r was computed. N (total independent repli-
cates per group) and p values are indicated in figure
legends. All graphs include mean with individual data
points shown. Outlier analysis was done using the
ROUT method embedded in Prism with a Q = 1%.
Results
ß-hexosaminidase-deficient Sandhoff disease model mice
exhibit robust alpha-synuclein and ubiquitin
accumulation in the brain
To assess the impact of loss of lysosomal hydrolase ß-hex-
osaminidase (HEX) activity and concurrent ganglioside
GM2 accumulation on alpha-synuclein (aSYN) homeosta-
sis, total aSYN content was measured in whole brain sam-
ples collected from HEXB-deficient Sandhoff disease (SD)
mice. Relative to age-matched WT littermates, SD whole-
brains contained significantly elevated total (~ 2.5-fold)
high molecular weight (HMW) aSYN species (Fig. 1a, b).
Levels of monomeric ~ 17 kDa aSYN (aSYN17) were un-
changed comparing the two cohorts (Fig. 1c). Prior histo-
logical studies have described ubiquitin inclusions in the
SD mouse model [9, 49]. To provide biochemical evi-
dence, WT- and SD whole-brain lysates were probed for
ubiquitin (Fig. 1d). A significant ~ 2.5-fold increase in ubi-
quitin was detected in membrane-enriched SDS-soluble
fractions (Fig. 1e). Ubiquitin accumulation was also veri-
fied by immunofluorescent co-labeling of aSYN and ubi-
quitin in SD mouse SNpc, which showed the presence of
numerous aSYN+/ubiquitin+ inclusions (SFIG. 1A). Inter-
estingly, the majority of larger ubiquitin+ inclusions did
not contain aSYN+ immunoreactivity.
Neuron-targeted overexpression of ß-hexosaminidase
subunits A and B significantly increases lysosomal
enzymatic activity and increases GM2 turnover
To determine whether an upregulation of HEX activity
could protect nigrostriatal dopaminergic neurons from
neuron-targeted AAV6-mediated human WT-aSYN
toxic overexpression in the rat substantia nigra pars
compacta (SNpc), which normally produces progressive
loss of tyrosine hydroxylase (TH+) dopaminergic neu-
rons [21, 54], we overexpressed HEX subunits A and B
using AAV6 in the same region (Fig. 2a). HEX enzymatic
function requires assembly of a HEXA+B heterodimer
with subsequent translocation to the lysosomal lumen
[2] (‘HEX’ refers to the combined expression of both
AAV6-HEXA- and B vectors.) To localize differential
enzymatic activity spatially in AAV6-HEX injected rat
brain, a histochemical HEX activity stain was used as
previously described [9] (Fig. 2b). In HEXA+B injected
rat SNpc, there was a clear increase of HEX activity in
the targeted region relative to the non-injected contra-
lateral hemisphere. This was verified by enzymatic activ-
ity measurements of lysosomal HEX in dissected SN
from a subset (n = 2) of HEX-injected rats relative to
CTRL+aSYN injected animals (n = 4) (Fig. 2c). In the
remaining animals (n = 2), there was no increase in HEX
activity in injected SN relative to non-injected SN (data
not shown). Potentially, this could be due to mistarget-
ing of the initial viral injection, or insufficient targeting
of the dissection, which could mask effects of viral HEX
expression due to high baseline HEX activity in the
surrounding tissue. The enzymatic upregulation was
dependent on concurrent expression of both subunits, as
single injections with either AAV6-HEX A or B did not
produce any discernible effects on enzymatic activity
(SFIG. 2A, B).
HEX acts on ganglioside GM2 by hydrolysis, generating
substrate GM3 [40]. In aSYN+HEX AAV6-injected SN,
there was a significant accumulation of GM3 content
compared to AAV6-CTRL+aSYN-injected SN (Fig. 2d).
HEX is a lysosomal enzyme, and its localization to lyso-
somes was verified with HEX A and LAMP-1 co-
immunofluorescent labeling (SFIG. 3). Additionally, HEX
overexpression was determined by quantification of #
HEX A+ puncta/TH+ cell in the injected SNpc relative to
the non-injected control hemisphere, which revealed a sig-
nificant ~ 20-fold increase in HEX A content per TH+ cell
(Fig. 2f). AAV6-driven expression of aSYN was robust
throughout both the striatum and SNpc at 12 weeks post-
injection (Fig. 2e). To rule out potential interference of the
HEXA- and B viral vectors on AAV6-mediated aSYN
overexpression, prior to stereological analysis and densi-
tometry of striatal TH, successful delivery of viral trans-
genes was determined in all animals using experimenter-
blinded visualization of human aSYN. This ensured only
animals with robust transduction of human aSYN-
expressing vector in the SN and STR were used, which in-
cluded HEX+aSYN injected animals (SFIG. 4).
Boosting ß-hexosaminidase activity protects the
nigrostriatal dopaminergic circuit from alpha-synuclein-
induced neurotoxicity
Having verified the viral-mediated upregulation of HEX
enzymatic activity and concurrent accelerated GM2/
GM3 conversion, the impact of this enzymatic boost on
AAV6-CTRL+aSYN associated loss of nigrostriatal
dopaminergic content was assessed by histological label-
ing of the enzyme TH in the rat SNpc. Nigrostriatal
dopaminergic projections terminate in the dorsolateral
aspect of the striatal caudate-putamen [4], and the
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integrity of these synapses are integral for proper func-
tioning of dopamine signaling in motor control.
Upon quantification, a significant ~ 10% loss of striatal
TH+ immunoreactivity was observed in AAV6-aSYN
injected dorsolateral aspects of the striatum that was res-
cued by co-expression with AAV6-HEX (Fig. 3a, c).
Changes in TH+ cell bodies of the substantia nigra pars
compacta SNpc was assessed by an optical fractionator
stereological probe [18]. A significant loss of ~ 35% TH+
neurons was found in AAV6-aSYN transduced animals
that was rescued by HEX co-expression (Fig. 3b, d).
Lastly, when comparing cell loss in the SNpc with accu-
mulation of overexpressed aSYN in the dorsolateral stri-
atum as measured by average fluorescence intensity, a
significant inverse correlation was identified (Fig. 3e).
Upregulation of ß-hexosaminidase activity prevents
nigrostriatal accumulation of AAV6-overexpressed alpha-
synuclein
Subsequent experiments tested how the HEX enzymatic
function might modulate aSYN content in these regions.
Utilizing differential ultracentrifugation, spot-dissected
rat ventral midbrain containing SN, and striatum from
CTRL+aSYN- and aSYN+HEX injected animals were
homogenized and fractionated into Triton X-soluble
cytosolic fractions, and Triton X-insoluble/SDS-soluble
membrane enriched fractions (Fig. 4a). Cytosol-
associated aSYN was unchanged in both CTRL+aSYN
and HEX+aSYN AAV6-injected SN relative to the non-
injected hemispheres (Fig. 4b, c). At the level of the stri-
atum, a significant, near 3-fold accumulation of cytosolic
Fig. 1 High molecular weight aSYN and ubiquitin accumulation accompany HEX-deficiencies in the Sandhoff mouse model. a Representative
immunoblot of high molecular weight (HMW) aSYN in whole-brain homogenates from age-matched WT and SD mice. GAPDH is shown as
loading control. b Densitometric quantifications of HMW-aSYN (>17kDA) of samples treated as in (a), normalized by GAPDH and expressed as
folds of WT (*:p < 0.05, Welch’s t-test). c Densitometric quantifications of monomeric aSYN17 over GAPDH. d Representative immunoblot of
ubiquitin in age-matched WT- and SD mouse whole-brain. GAPDH is shown as loading control. e Densitometric quantifications of total ubiquitin
over GAPDH, expressed as folds of WT (***:p < 0.001, two-tailed t-test). Box plots show median, 95% CI and range, with individual data points
shown for all graphs, n = 7–8 / group
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aSYN17 monomer could be detected, which was re-
stored to baseline levels relative to the non-injected
hemisphere in HEX+aSYN co-injected SN (Fig. 4d, e). In
SDS-soluble, membrane enriched fractions, monomeric
aSYN17 was significantly increased (~ 2-fold) in CTRL+
aSYN injected SN relative to the non-injected hemi-
spheres with HEX co-expression restoring levels to base-
line (Fig. 4f, g). Striatal membrane-associated aSYN
content was not changed in these animals (Fig. 4h, i).
aSYN+ inclusions in both CTRL+aSYN and HEX+aSYN
Fig. 2 AAV6-expressed HEX subunits A and B localize to lysosomes and boost enzymatic activity in the rat substantia nigra. a Adult rats received
unilateral SNpc injections of AAV6s expressing either aSYN and a control vector, or aSYN+HEX subunits A and B. Biochemical and histological
measurements were collected at 12 weeks post-injection, and comparisons were made between injected- and non-injected control hemispheres
for each animal. b HEX activity histochemical detection assay (red precipitate) in a rat injected with AAV6s expressing HEX subunits A and B.
(SNr = substantia nigra pars reticulata, VTA = ventral tegmental area). Boxed inserts are shown in higher magnification below. c Lysosomal HEX
activity measured by artificial 4-MU-substrate in dissected SN from rats injected with CTRL+aSYN (n = 4) and HEX+aSYN (n = 2) (****:p < 0.0001,
two-tailed t-test). d HPLC measurements of GM3 in spot-dissected ventral midbrain from control+aSYN and HEX+aSYN injected rats, normalized
by the non-injected hemispheres (n = 4 / group). e Representative immunofluorescent micrograph showing AAV6-overexpressed human WT
aSYN (magenta) in dopaminergic neurons (TH+) (green) in the rat striatum and SNpc. f Quantifications of # HEX A+ puncta / TH+ cell in images
as in SFIG. 3 (n = 4 / group) (*:p < 0.05, Welch’s t-test)
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AAV6-injected SNpc were consistently co-labeled by ubi-
quitin (SFIG. 1B).
ß-hexosaminidase expression decreases aSYN-association
to lipid compartments
To measure association of lipids with aSYN in the
injected SN of AAV6-CTRL+aSYN and AAV6-HEX+
aSYN transduced rats, lipids were extracted from SDS-
soluble membrane enriched (+) fractions, and aSYN im-
munoreactivity was compared to that of an equal
amount of untreated, lipid-containing (−) homogenate in
AAV6-injected dissected SN. Heating of lysates at 65C
for 16 h separates protein- and lipid phases, and any pro-
tein signal that is enriched post-delipidation implies
embedding of epitopes in lipid compartments [20, 45]
(Fig. 5a).
Strikingly, upon lipid extraction of AAV6-CTRL+aSYN
injected membrane-enriched SN homogenates, a 10-fold
increase in HMW-aSYN immunoreactivity was detected
compared to the untreated fractions, that was prevented
by co-expression of HEX (Fig. 5b, c). Monomeric aSYN17
abundance was not altered by delipidation (Fig. 5d). When
comparing lipid-extracted HMW-aSYN abundances with
that of aSYN17 detectable in SDS-soluble membrane-
enriched fractions within the same animals (see Fig. 4f, g),
the two compartments were linearly correlated (Fig. 5e).
Interestingly, though ~ 60% of CTRL+aSYN-injected
animals had robust aSYN phosphorylation in injected
Fig. 3 HEX co-expression rescues aSYN-associated loss of nigrostriatal TH content. a Representative immunofluorescent micrograph showing TH
(greyscale) in the striata of rats injected with AAV6-CTRL+aSYN or aSYN+HEX. Dashed red lines indicate the dorsolateral aspect of the caudate-
putamen (b) Representative micrograph of TH-DAB stained SNpc in rats injected with AAV6-CTRL+aSYN or aSYN+HEX. Boxed inserts are shown in
higher magnification below. (c) Densitometric quantifications of average TH+ immunofluorescence intensity measured in the indicated regions,
presented as in (a). *:p < 0.05, Welch’s t-test, n = 6 and 9 / group). d Unbiased stereological estimates of # TH+ cell profiles per SNpc, expressed as
% of the non-injected hemisphere per animal (dotted line). *:p < 0.05, Welch’s t-test, n = 6 and 9 / group). Data represent median, 95%CI and
range, with individual data points shown. e Pearson’s correlation analysis of TH+ cell counts from (d) with average striatal aSYN+
immunofluorescence (AFUs) in the region indicated in (a) (N = 13)
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Fig. 4 (See legend on next page.)
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SNpc that was prevented by HEX co-expression
(SFIG. 5A), lipid extraction did not alter the abundance
of this signal (SFIG. 5B). In SD mouse whole-brain,
phosphorylated aSYN (p-aSYN) was clearly detectable
with no signal in age-matched WT mice (SFIG. 5C).
Discussion
HEX activity prevents aSYN embedding in lipid
compartments
This investigation revealed that AAV6-overexpressed
aSYN in the rat SNpc embedded within lipid compart-
ments and accumulated there at a 5-fold amount com-
pared to the accumulation of aSYN observed in both
cytosolic- and membrane-enriched fractions. Boosting
physiological HEX enzymatic function by AAV6-driven
expression of HEX subunits A and B increased GM2/
GM3 conversion and prevented the protein-lipid interac-
tions by aSYN. Physiological aSYN strongly binds ganglio-
sides [11, 25, 47], but previous studies in aSYN-ganglioside
protein-lipid interactions have arrived at opposing conclu-
sions regarding the outcomes of this interaction. A previous
in vitro study reported binding by all a-series gangliosides -
including GM1, GM2, and GM3 – to inhibit aSYN fibril
formation [27], while a more recent in vitro report on the
contrary found GM1 and GM3 to be potent accelerators of
aSYN aggregation [13]. However, given that the primary
physiological interaction of aSYN with gangliosides is
localization of aSYN to synaptic terminals through binding
of ganglioside-enriched lipid raft domains [12] in vitro sys-
tems are limited in providing accurate physiological condi-
tions. Interestingly, the present report reveals a significant
in vivo association of AAV6-expressed aSYN with total
lipids in rat dopaminergic neurons that can be prevented
by increased HEX activity; nonetheless, the lipid extraction
assay does not address the specific compartments in which
this interaction takes place. However, based on prior studies
showing relative enrichment of gangliosides in specialized
synaptic lipid raft domains, and the increased GM2/GM3
ratio reported in this study after AAV6-HEX expression,
synaptic and vesicular domains are likely sites of over-
expressed aSYN protein-lipid interactions. It is also
noteworthy that lipid extraction produced no changes
in p-aSYN detection in AAV6-CTRL+aSYN or HEX+
aSYN co-injected SNpc. This is in line with prior work
which demonstrated reduced lipid membrane binding
by p-aSYN oligomers in vitro [31].
The effect of HEX loss of function on aSYN in Sandhoff
disease models
The SD mouse line, wherein targeted disruption of the
HEXB locus causes complete loss of HEX function and
severe early-onset neuropathology [42], is an ideal sys-
tem for investigating changes in physiological aSYN
stemming from ganglioside GM2 accumulation. Prior
studies have provided histological evidence for aSYN ac-
cumulation in the SD mouse line [9, 49], but there have
been no corroborations at a biochemical level to date. In
the present study, HMW-aSYN species in SD brain were
2.5-fold enriched compared to age-matched WT litter-
mates. The current data demonstrate that loss of the
ability to catabolize GM2 in the lysosome coincides with
widespread HMW-aSYN formation in the brain.
In addition to the HMW-aSYN accumulation, there
was a significant increase of polyubiquitin in the SD
mouse brain. Accumulation of polyubiquitinated pro-
teins can be indicative of impaired proteolysis through
both the ubiquitin-proteasome- and lysosome-systems,
and reduced activity of the ubiquitin C-terminal hydro-
lase UCH-L1 has been noted in the brains of the SD
mouse model, as well as in cultured cells from numerous
other lysosomal storage disorders patient samples [3]. A
study by Cachón-González et al. [9] demonstrated re-
versibility of ubiquitin accumulation in the SD mouse
with AAV6-mediated HEX overexpression, indicating
that ganglioside homeostasis influencing lipid rafts may
impact essential downstream cellular functions, includ-
ing general ubiquitin-proteasome (UPS) and autophagy-
lysosome (ALP) function, in addition to modulating
aSYN protein-lipid interactions. In this current study,
we did not detect changes in any UPS- or ALP-
associated proteins in AAV6-CTRL+aSYN or HEX+
aSYN-injected rat SNpc (data not shown). In this report,
we demonstrate numerous ubiquitin+ inclusions in SD
mouse SNpc that were not co-labeled by anti-aSYN anti-
bodies, while conversely in AAV6-CTRL+aSYN and
HEX+aSYN co-injected rat SNpc, the majority of aSYN+
inclusions were ubiquitin co-positive. From this, it would
appear that in SD mice with complete loss of HEX
(See figure on previous page.)
Fig. 4 Upregulation of ß-hexosaminidase activity prevents nigrostriatal accumulation of AAV6-overexpressed alpha-synuclein. a Triton X-soluble
(TRT) cytosolic fractions, and Triton X-insoluble/SDS-soluble membrane enriched fractions (SDS) were prepared by sequential ultracentrifugation
of homogenized spot-dissected SN lysates. b, d Representative immunoblots of TRT-soluble aSYN in CTRL+aSYN and HEX+aSYN AAV6-injected SN
(b) and striatum (d) relative to their non-injected control hemispheres. c, e Densitometric quantifications of aSYN normalized by GAPDH,
expressed as fold change from the non-injected hemisphere per animal (dotted line) in the SN (c) and striatum (e) (*:p < 0.05, two-tailed t-test). f,
h Representative immunoblots of SDS-soluble aSYN in CTRL+aSYN and HEX+aSYN AAV6-injected SN (f) and striatum (h) relative to their non-
injected control hemispheres. g Densitometric quantifications of SN SDS-soluble aSYN normalized by GAPDH, compared to the non-injected
control hemisphere per animal (*:p < 0.05, paired ratio matched sample t-test). i Densitometric quantifications of STR SDS-soluble aSYN
normalized by GAPDH, expressed as fold of non-injected control hemisphere. n = 5–7 / group for all graphs
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function there exists generalized impairments to UPS/
ALP function that is not directly associated with aSYN
pathology.
Elevated HEX activity protected the nigrostriatal
dopaminergic circuit from aSYN-associated neurotoxicity
The neuroprotective potential of AAV6-HEX expression
in dopaminergic neurons of the rat SNpc was determined
in an AAV6-aSYN based model of synucleinopathy. Using
this paradigm, upregulated HEX activity rescued dopa-
minergic neurons from degeneration caused by AAV6-
overexpressed aSYN at the level of both SNpc cell bodies,
and their terminals in the dorsolateral striatum. This
synucleinopathy model is informative as it overexpresses
human aSYN in the SNpc without insertion of transgenes
into the animal. However, given that this is a surgically
placed vector, care must be taken in addressing variability
caused by the actual location and expression of the
Fig. 5 HEX co-expression prevents aSYN association with lipid compartments. a Illustration of the lipid extraction paradigm. Protein-lipid
interactions may mask or modulate epitopes and alter detection by antibodies. Delipidation would extract these complexes and allow detection
by conventional methods. b Representative immunoblot of aSYN17 monomer and HMW-aSYN in CTRL+aSYN or HEX+aSYN AAV6-injected rat SN,
either untreated (−) or lipid extracted by heating at 65C for 18 h (+). c Densitometric quantifications of HMW-aSYN immunoblots from lipid
extracted fractions (+) expressed as % of the lipid containing (−) fraction (*:p < 0.05, Welch’s t-test, n = 5 and 7 / group). d Quantifications as in (c)
for aSYN17 monomer (n = 6 and 7 / group). Data represents median, 95% CI and total range with individual data points shown for all graphs. e
Pearson’s correlation analysis of aSYN-HMW measurements as in (c) with SDS-soluble aSYN17 / GAPDH values from Fig. 4g (N = 10)
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transgene. The AAV6-aSYN titers selected for infusion
into the SNpc in this study produced a mild ~ 35% loss of
TH+ neurons in the SNpc. There was an average ~ 10% re-
duction in striatal TH density, possibly relating to the
known relative increase in striatal TH prior to degener-
ation in models of aSYN overexpression [22, 33]. Given
this less toxic dose, there is a greater chance of measuring
specific interactions between aSYN and HEX-dependent
ganglioside metabolism, as neuronal loss is limited. Fur-
thermore, there was no aSYN+ immunoreactivity detect-
able in SDS-insoluble SNpc homogenate fractions from
these animals, showing that in this model there was no
formation of insoluble fibrillar or amyloid aSYN species
contributing to the pathology. This was also verified in
SDS-insoluble whole-brain homogenate fractions from SD
mice, which similarly had no detectable aSYN+ immuno-
reactivity (data not shown).
AAV6-HEX overexpression increased GM2/GM3 turn-
over. One interpretation is that, given the preferential en-
richment of gangliosides in lipid raft domains of the plasma
membrane, the observed reduced lipid binding of aSYN by
HEX overexpression was mediated by increased turnover of
GM2/GM3 in these compartments. However, it is probable
that the impact of altered ganglioside abundance depends
on the context, which in our experimental system was one
of increased aSYN protein burden. In another context, in
Galgt1−/− transgenic mice lacking GM2 synthase, GM2
content is fully depleted, but - similarly to SD mice present-
ing with an overabundance of GM2 - they develop early
HMW-aSYN formation and dopaminergic neuron degener-
ation, in addition to a severe motor phenotype [53]. In the
Galgt1−/− mice, administration of a brain penetrant GM1
analog rescued these deficits, which demonstrates the
crucial importance of a neuronal ganglioside on physio-
logical aSYN function and overall cellular viability. In
human PD SNpc, levels of major ganglioside biosyn-
thesis enzymes are decreased in neuromelanized dopa-
minergic neurons, but not proximal, non-melanized
cells [43], indicative of cell-type specific impairments in
ganglioside metabolism. These findings were confirmed
in a separate study, which by HPLC measurements of
human post-mortem PD-patient SN found all major
gangliosides to be significantly reduced relative to age-
matched healthy subject controls, which in PD subjects
were reduced in an age-dependent fashion [17]. Cere-
brospinal fluid measurements taken from these same
patients revealed significantly increased GM3/GM2 ra-
tios, which could indicate a compensatory drive to-
wards enrichment of these gangliosides through
alternate metabolic harvesting pathways, as overall
HEX activity in the SN of PD patients was decreased.
The critical importance of GM3 homeostasis on neur-
onal development and function can be gleaned from
studies in Sat-1−/− GM3 synthase deficient mice with
complete GM3 depletion, which present with develop-
mental neurodegenerative abnormalities and numerous
behavioral deficits [30, 55].
In summary, this report characterizes the neuroprotec-
tive effect of increased HEX enzymatic activity on aSYN-
induced degeneration of dopaminergic neurons in vivo,
which appears to be mediated - at least in part - by re-
duced aSYN in lipid compartments. Future work should
aim to identify the specific lipid compartments in which
GM2/GM3 content appear to modulate aSYN incorpor-
ation, to better understand the cellular processes most
vulnerable to impaired ganglioside homeostasis in disor-
ders of the central nervous system.
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Additional file 1: Supplementary Fig. 1. aSYN-ubiquitination in the
SD-TG mouse model and in AAV-aSYN-injected rat SNpc. (A) Representa-
tive micrograph of aSYN (green) and ubiquitin (magenta) in age-matched
WT- and SD-TG mouse SNpc. Filled arrowheads indicate ubiquitin+
aSYN+ inclusions. Open arrowheads indicate ubiquitin+ aSYN- inclusions.
Boxed inserts are shown in higher magnification with orthogonal view
on right. Scale bar = 15um. (B) Representative micrograph of aSYN
(green) and ubiquitin (magenta) in non-injected and AAV-CTRL+aSYN
and HEX+aSYN injected rat SNpc. Arrowheads indicate ubiquitin+ aSYN+
inclusions. Boxed inserts are shown in higher magnification with orthog-
onal view on right. Scale bar = 15um. Supplementary Fig. 2. AAV6-
mediated expression of HEX subunits A and B alone does not elicit up-
regulation of enzymatic activity (A) HEX activity histochemical detection
assay (red precipitate) in a rat injected with AAV6 expressing HEX subunit
B. (SNr = substantia nigra pars reticulata, SNpc = substantia nigra pars
compacta, VTA = ventral tegmental area). Boxed inserts are shown in
higher magnification below. (B) High magnification inserts of tissue pre-
pared as in (A), in SNpc injected (1) with AAV6-HEX A, and the non-
injected control hemisphere (2). Supplementary Fig. 3. Overexpressed
HEX localizes to lysosomes in transduced TH+ neurons of the rat SNpc.
Representative immunofluorescent micrograph showing HEX subunit A
(red) and LAMP-1 (greyscale) in TH+ dopaminergic neurons (green) in
the SNpc of AAV6-HEX injected- and non-injected hemispheres. Dotted
outline represents TH+ cell profile. Boxed insert is shown in orthogonal
view (YZ). Supplementary Fig. 4. Representative immunofluorescent
micrograph showing AAV6-overexpressed human WT aSYN (magenta) in
dopaminergic neurons (TH+) (green) in the rat striatum and SNpc of an
animal injected with AAV6-aSYN, HEXA and HEXB (STR = striatum, VTA =
ventral tegmental area, SNpc = substantia nigra pars compacta, SNr = sub-
stantia nigra pars reticulata.) Supplementary Fig. 5. Phosphorylated
aSYN is a feature of both AAV-mediated aSYN overexpression and HEX
loss-of-function. (A) Immunoblot of S129-phosphorylated aSYN (p-aSYN)
in CTRL+aSYN and HEX+aSYN AAV-injected and non-injected rat SNpc.
GAPDH is shown as loading control. (B) Immunoblot of p-aSYN CTRL+a-
SYN-injected SNpc containing lipids (+) or after lipid extraction at 65C for
16 h(−). (C) Immunoblot of p-aSYN in age-matched WT- or Sandhoff
transgenic (SD) mouse whole-brain. GAPDH is shown as loading control.
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